Grants Search Results

This grant supports clinical research staff to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Cancer treatment outcomes in patients between ages 13-39 years (adolescent and young adults - AYA) have been quite dismal. Clinical trials are cancer treatment options which potentially offers newer drugs in the hopes to cure cancer. One of the reasons for poor outcomes is limited participation of AYA cancer patients in clinical trials. This grant supports a Clinical Research Coordinator to ensure that more adolescent and young adults can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to support the childhood Cancer Survivor Program (cCSP) and ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a research nurse and clinical data manager to oversee the development and implementation of an integrated medicine program for pediatric oncology patients, opening and coordinating new clinical trials to integrate complementary therapies for pediatric cancer and bone marrow transplant patients.

This grant supports a Research Coordinator for the Targeted Therapeutics program, to ensure that more kids can be treated on targeted genomic clinical trials, which have not been widely available in North and West Texas.

This grant supports a patient navigator to ensure that more adolescents and young adults (AYA) can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Nurse Coordinator for the Adolescent Young Adult Cancer Center Program at Bon Secours St. Francis Health System, to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports bilingual clinical research staff to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

Memorial Health University Medical Center has developed a dedicated Adolescent and young adult (AYA) cancer program to provide better care and to encourage participation of these patients in clinical trials that will ultimately lead to better treatment outcomes.This grant supports a Clinical Oncology Social Worker to support the AYA Cancer Program and ensure that more AYA patients can be treated on clinical trials, often their best hope for a cure.

This grant supports a Research Nurse to ensure that more kids can be treated on clinical trials, often their best hope for a cure.

This grant supports a Clinical Research Associate to facilitate early-phase pediatric oncology clinical trials in the South Plains Oncology Consortium (SPOC) and ensure that more kids can be treated on clinical trials, often their best hope for a cure.

The AJ Renner Memorial St. Baldrick's Infrastructure Grant funds the Nurse Researchers in the UIC/Rush/Stroger COG Program to ensure more kids can be treated on clinical trials, often their best hope for a cure. AJ Renner was an amazing volunteer and donor in Chicago and a champion for kids fighting cancer.

This grant supports a scientific meeting to plan a clinical trial for osteosarcoma, focused on using genomic data to define subgroups to receive targeted therapy combined with chemotherapy.

Based on progress to date, Dr. Tarlock was awarded a new grant in 2020 to fund an additional year of this Scholar grant. Acute myeloid leukemia (AML) is a cancer of white blood cells and almost half of children diagnosed with AML will not be cured, even with very intensive chemotherapy and in some cases bone marrow transplant. Many of the mutations in the leukemia that contribute to development of the cancer have been identified, but cannot be used for therapeutic benefit, especially in children. Dr. Tarlock and colleagues have performed genomic testing on the cells of many children diagnosed with AML and found that approximately 40% of children abnormally express the protein mesothelin on their leukemia cells. Dr. Tarlock and colleagues will develop a phase I clinical trial to test a new therapy strategy that uses principles of the immune system to deliver chemotherapy only to mesothelin-positive leukemia cells. They will develop a clinical assay for mesothelin detection in AML to identify children who will benefit from mesothelin-targeted therapy, and investigate methods to optimize disease response to mesothelin-targeting immune therapies.

This grant is generously supported by Rhys’ Pieces of the Cure, a Hero Fund created to honor Rhys Goldman and his journey with cancer. He was diagnosed with pre-B acute lymphoblastic leukemia just 2 weeks before his 6th birthday and endured treatment for three years. Rhys missed a lot of school and life during those years but since marking the end of treatment in July 2018, he has been enjoying swimming, singing in a boys’ choir, chess tournaments, playing with his dogs and going to school. Rhys’ Pieces for the Cure was created to ensure more research is funded for the treatment of pediatric cancer that is specifically focused on less toxic cures for kids.

While great strides have been made in treating children with acute leukemia, some children continue to do poorly. For example, children of Hispanic ethnicity are at greater risk of both relapse and treatment-related complications. The Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium will expand and enhance an established network of childhood cancer centers, with the goal of tackling ethnic outcome disparities by generating an unmatched resource of clinical information and biological samples. This information will be used to predict those who have the greatest risk of poor outcomes, with a focus on those of Hispanic ethnicity, to improve prevention and treatment strategies.

This grant is generously supported by Micaela's Army Foundation which was established in loving memory of Micaela White who fiercely fought Acute Myeloid Leukemia at the age of 18. Their mission is to raise money to help fund cancer research, education, awareness, and patient support for the cancers that affect children and their families.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium. For a description of this project, see the consortium grant made to the lead institution: Baylor College of Medicine, Houston, TX.